Desmopressin for the Treatment of Orthostatic Hypotension and Excessive Nighttime Urination in Parkinson’s Disease

A Double-Blind, Placebo-controlled Crossover Clinical Trial of Desmopressin for the Treatment of Orthostatic Hypotension and Nocturia in Parkinson’s Disease

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000080224

Enrollment

Registered

2009-02-03

Start date

2009-04-06

Completion date

2009-11-01

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

We plan to study 20 patients with idiopathic Parkinson's disease with complications of orthostatic hypotension and nocturia. In an 8 week double-blinded, crossover study design, we will study the effects of oral desmopressin (or matching placebo) on orthostatic hypotension, nocturia, and sleep.

Interventions

Subjects will start with either nightly placebo or oral desmopressin for three weeks. After a washout period of one week of no medication, they will then switch to the therapy they have not tried for another three weeks. Subjects taking desmopressin will begin with a 100 mcg nightly dose. If this is tolerated, after one week they will increase to 200 mcg nightly, which they will take for two weeks.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

30 Years to 85 Years

Healthy volunteers

Inclusion criteria

Parkinson's disease Orthostatic hypotension (blood pressure drop with standing) A need to empty the bladder 2 or more times at night

Exclusion criteria

History of renal failure, congestive heart failure, or cirrhosis A history of low blood sodium Dementia

Outcome results